Tendinopathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tendinopathy Market Outlook

Thelansis’s “Tendinopathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Tendinopathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Tendinopathy Overview

Tendinopathy refers to a wide range of painful disorders that result from overuse in the tendons and surrounding tissues. Patients with tendon injuries range widely in age from active athletes to non-athletes. Patients are more susceptible to certain tendinopathies due to their participation in certain activities and vocations. Tendinosis etiology has yet to be entirely understood. Considering the history and physical exam results, X-rays ought to be taken if there is any doubt about bone damage. Similar to other musculoskeletal conditions, tendinosis is initially treated conservatively. The first recommendations should be rest, cryotherapy, and eccentric exercises with a physical or occupational therapist. The effectiveness of oral and topical NSAIDs in the management of tendinopathy. Steroid injections were a standard treatment in the past, but they are no longer the first line of treatment. Steroid injections are used to reduce pain in the short term. Glyceryl trinitrate patches are an FDA-approved medication used off-label to treat tendinopathy. A class of enzymes known as nitric oxide synthases (NOS) produces the soluble chemical nitric oxide (NO). NO can be harmful in high concentrations, but it functions as a cellular messenger in physiologically relevant quantities and may be involved in host defense, memory, and blood pressure. After an injury, NO is a part of tendon repair. Professional basketball and roller hockey players have the highest incidence of tendinopathy. In team sports, tendinopathies account for many injuries and are more prevalent in professional teams than in young leagues, particularly basketball and roller hockey.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: